Order Article Reprints

Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, et al. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers. 2019; 11(12):1987. https://doi.org/10.3390/cancers11121987

Schneeweiss, Andreas, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Apostolia M. Tsimberidou, Cynthia Ma, Sara A. Hurvitz, Christine Rentzsch, Marion Rudolph, and et al. 2019. "Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy" Cancers 11, no. 12: 1987. https://doi.org/10.3390/cancers11121987

Schneeweiss, A., Hess, D., Joerger, M., Varga, A., Moulder, S., Tsimberidou, A. M., Ma, C., Hurvitz, S. A., Rentzsch, C., Rudolph, M., Thiele, S., Boix, O., Wilkinson, G., Lagkadinou, E., & Ocker, M. (2019). Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers, 11(12), 1987. https://doi.org/10.3390/cancers11121987